Merck KGaA
OTC:MKGAF
Merck KGaA
OTC:MKGAF
Price:
127.814
USD
2.95%
Market Closed
Market Cap:
$55.6B
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
M
|
Merck KGaA
OTC:MKGAF
|
DE |
|
I
|
InterCard Informationssysteme AG
F:II8
|
DE |
|
China Resources Mixc Lifestyle Services Ltd
HKEX:1209
|
CN |
|
L
|
Laguna Resorts and Hotels PCL
SET:LRH
|
TH |
|
B
|
Belgravia Hartford Capital Inc
CNSX:BLGV
|
CA |
|
L
|
Luxchem Corporation Bhd
KLSE:LUXCHEM
|
MY |
|
K
|
Kawagishi Bridge Works Co Ltd
TSE:5921
|
JP |
|
Kuang-Chi Technologies Co Ltd
SZSE:002625
|
CN |
|
EZCORP Inc
NASDAQ:EZPW
|
US |
|
E
|
Eletromidia SA
BOVESPA:ELMD3
|
BR |
|
T
|
Tyme Technologies Inc
F:RFL
|
US |
|
STINAG Stuttgart Invest AG
F:STG
|
DE |
|
Elgi Equipments Ltd
NSE:ELGIEQUIP
|
IN |
|
A
|
Ananti Inc
KOSDAQ:025980
|
KR |
|
Divi's Laboratories Ltd
NSE:DIVISLAB
|
IN |
|
Shandong Gold Mining Co Ltd
SSE:600547
|
CN |
|
I
|
Imperium Financial Group Ltd
HKEX:8029
|
HK |
Multiples-Based Value
The Multiples-Based Value of one
MKGAF
stock under the Base Case scenario is
hidden
USD.
Compared to the current market price of 127.814 USD,
Merck KGaA
is
hidden
.
Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
MKGAF Multiples-Based Value
LOCKED
Multiples Across Competitors
MKGAF Competitors Multiples
Merck KGaA Competitors
Merck KGaA Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| DE |
|
Merck KGaA
OTC:MKGAF
|
46.5B USD | 2.2 | 17.5 | 8.1 | 12.4 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
829.8B USD | 12.7 | 40.2 | 27.2 | 29 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
579B USD | 6.1 | 21.6 | 15 | 18.4 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 4 | 19.3 | 11.5 | 12.9 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
296B USD | 4.6 | 16.2 | 10 | 12.2 | |
| CH |
|
Novartis AG
SIX:NOVN
|
229.3B CHF | 5.2 | 21.1 | 13 | 16.8 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
214.5B GBP | 5.1 | 29.1 | 16.1 | 22.7 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
237.1B USD | 102.3 | -81.1 | 375.3 | 941.3 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1T DKK | 3.3 | 9.8 | 7.3 | 8.6 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
153.7B USD | 2.5 | 19.8 | 7.6 | 10.2 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
117.8B USD | 2.4 | 16.7 | 7.1 | 8.7 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
